 |
|
|
| |
|
HCV at CROI 2015 - 38 Reports + Cost-Effectiveness studies recently published, recent NYS Medicaid Hearing results
|
| |
| |
- Summary from CROI 2015 for Hepatitis C HIV/HCV coinfected patients are no longer a difficult to treat special patient population. What can we learn from new clinical phase III studies and feedback from real-life cohorts receiving modern DAA-based therapy? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/24/15)
- Modeling the Impact of Deferring HCV Treatment [to F3/F4 vs F2 or sooner: 1 month/year after diagnosis) on Liver-Related Events in HIV+ Patients....outcomes: liver-related events & infectious duration....by Swiss HIV & HCV Cohort....model finds delay in treatment increased 2-times to 5 times risk in developing decompensation, HCC & liver-related death - (03/27/15)
The 24th Annual Meeting
of the Asian Pacific Association for
the Study of the Liver (APASL 2015)
Istanbul, Turkey, March 12-15, 2015
Treatment
- The Burden of Liver Disease among Persons with Hepatitis C in the United States...."the need is urgent to identify HCV-infected persons & link them to management & care" screening - (03/06/15)
- ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir - (03/06/15)
- Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study - (02/27/15)
- Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (02/27/15)
- Drug Interactions Between the anti-HCV Regimen Ledipasvir/Sofosbuvir and Ritonavir Boosted Protease Inhibitors plus Emtricitabine/Tenofovir DF - (02/23/15)
- GILEAD ANNOUNCES SVR12 RATES FROM PHASE 3 STUDY EVALUATING HARVONI® FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV - (02/27/15)
- HIGH SVR REGARDLESS OF TIME TO SUPPRESSION WITH OMBITASVIR/PARITAPREVIR/R & DASABUVIR + RBV - (03/02/15)
- Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 A Randomized Trial - (02/24/15)
- SVR12 in over 90% of HCV/HIV null responders stating daclatasvir/asunaprevir plus PR - written by Mark Mascolini - (03/02/15)
CROI: Risk of late relapse or re-infection with Hepatitis C after Sustained Virological Response: meta-analysis of 66 studies in 11,071 patients - (03/11/15)
- HCV recurrence after SVR 20 times more frequent with HIV/HCV than HCV alone - written by Mark Mascolini - (02/23/15)
- CROI Big Stories: TAF safety/efficacy, new HIV ARTs attachment & maturation inhibitors; new HCV drugs study results in HIV/HCV coinfected - Harvoni, daclatasvir+sofosbuvir, Abbvie 3D - (Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin ) - written by Mark Mascolini - (03/02/15)
- Majority of HIV/HCV Co-Infected Patients Require Antiretroviral Therapy Switch Prior to Use of Simeprevir .....15% cant switch for resistance etc...31% on boosted PI cant switch - (03/25/15)
- Sofosbuvir/Daclatasvir in HIV/HCV Co-infected Patients With Extensive Liver Fibrosis - (03/25/15)
- Drug-Drug Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Dolutegravir - (03/25/15)
- Successful Treatment with Direct Acting Antivirals in HIV/HCV Patients ....95% SVR with Sim/Sof in real-world clinic setting/support services - (03/25/15)
- Real-world Data on HIV-Positive Patients with HCV Treated with Sofosbuvir and/or Simeprevir - (03/25/15)
- German cohort on sofosbuvir based therapy for HCV/HIV- and HCV-infection (GECOSO) - (03/25/15)
- Hematologic Analysis of Paritaprevir(ABT-450)/r/Ombitasvir and Dasabuvir + RBV in TURQUOISE-I - (03/25/15)
- Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious Adverse Events - (03/25/15)
- Sofosbuvir, Simeprevir, +/- Ribavirin in HCV G1 Protease Inhibitor-Experienced Patients [14/15 SVR 93%] - (03/09/15)
- Real-World Cost-per-SVR with Simeprevir/Sofosbuvir ± Ribavirin.... 88% SVR/76% SVR in PI-Experienced - (03/09/15)
- Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice - (03/09/15)
- Hepatitis C infection and Cognition in Older HIV+ Adults: Data from the Center of Excellence on Disparities in HIV and Aging (CEDHA) - (03/06/15)
- Has Modern ART Reduced Endstage Liver Disease Risk in HIV-Hepatitis Coinfection? ...... "No clear reduction in ESLD risk was observed over the 3 time periods" - (03/06/15)
- Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV - (03/20/15)
- Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons. Statins Reduce Plaque/Halt Carotid Artery Wall Thickening/Improve Kidney - (03/23/15)
- Marijuana Use Does Not Accelerate Liver Fibrosis in HCV/HIV-Coinfected Women - (03/20/15)
- Portal Pressure Changes After HCV Eradication in HIV/HCV+ Patients With Cirrhosis - (03/20/15)
- Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV ...... "SVR Associated with reduced risks of decompensation and death..... No decompensations were observed in HIV/HCV patients who achieved SVR" - (03/06/15)
- Impact of Integrating EMR HCV Testing Prompts in a Difficult to Navigate EMR System - (03/20/15)
- Characterization of Naturally Occurring Resistance to HCV NS5A Inhibitors - (03/20/15)
- SVR Durability: HCV Patients Treated with IFN-Free DAA Regimens - (03/06/15)
Cost-Effectiveness recent publications NOT CROI
- Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus - (03/18/15)
- Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States - (03/18/15)
- The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus and Editorial - (03/16/15)
- Cost-effectiveness of hepatitis C treatment
for patients in early stages of liver disease - (03/16/15)
- NYS DURB HCV Feb 26 2015 Hearing Summary Posted - (03/16/15)
- Utility of Hepatitis C Viral Load Monitoring with Ledipasvir ! and Sofosbuvir Therapy ! (week 4 testing in Harvoni NIH study) - (03/09/15)
- One Year Results of a Community-Based Hepatitis C Testing and Linkage to Care Program - (03/18/15)
- Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV Infected Patients - (03/09/15)
- Low HCV Testing Uptake of the Current Birth Cohort Guidelines....HCV Cascade - (03/09/15)
- Effect of HIV Co-infection on Adherence to a 12-week regimen of HCV Therapy with Ledipasvir/Sofosbuvir - (03/06/15)
- Chronic Kidney Disease Progression after HCV Seroconversion - (03/06/15)
|
|
| |
|
|
|
|
|
|
